Trial NCT03075553

View at ClinicalTrials.gov 
Org. Study IDs: MC1681
Secondary IDs: MC1681 NCI-2017-00307 P30CA015083

Last trial update was posted on 2020-04-21

MeSH Interventions

Nivolumab

MeSH Conditions

Enteropathy-Associated T-Cell Lymphoma Immunoblastic Lymphadenopathy Intestinal Diseases Leukemia Leukemia, T-Cell Leukemia-Lymphoma, Adult T-Cell Lymphoma Lymphoma, Extranodal NK-T-Cell Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Mycoses Mycosis Fungoides Recurrence

Other Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm HTLV-1 Infection Hepatosplenic T-Cell Lymphoma NK-Cell Lymphoma, Unclassifiable Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Anaplastic Large Cell Lymphoma Recurrent Angioimmunoblastic T-cell Lymphoma Recurrent Enteropathy-Associated T-Cell Lymphoma Recurrent Mycosis Fungoides Refractory Adult T-Cell Leukemia/Lymphoma Refractory Anaplastic Large Cell Lymphoma Refractory Angioimmunoblastic T-cell Lymphoma Refractory Enteropathy-Associated T-Cell Lymphoma Refractory Mycosis Fungoides Refractory Nasal Type Extranodal NK/T-Cell Lymphoma Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

Stopping Reasons

due to poor response

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID